Perspectives on T-cell engaging therapies in relapsed/refractory indolent non-Hodgkin lymphoma.

IF 2.4 4区医学 Q2 ONCOLOGY

Current Opinion in Oncology Pub Date : 2025-09-01 Epub Date: 2025-06-05 DOI:10.1097/CCO.0000000000001160

Max Bakker, Maria T Kuipers, Marie José Kersten, Sanne H Tonino, Yasmina I M Serroukh

{"title":"Perspectives on T-cell engaging therapies in relapsed/refractory indolent non-Hodgkin lymphoma.","authors":"Max Bakker, Maria T Kuipers, Marie José Kersten, Sanne H Tonino, Yasmina I M Serroukh","doi":"10.1097/CCO.0000000000001160","DOIUrl":null,"url":null,"abstract":"Purpose of review: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent subtypes of non-Hodgkin lymphoma (iNHL) characterized by a relapsing-remitting disease course. A promising novel therapeutic class emerges with T-cell engaging therapies, which include CD19 directed chimeric antigen receptor T-cell (CAR-T) therapy and CD3xCD20 directed bispecific antibodies (BsABs). This review provides a comprehensive evaluation of their efficacy and safety along with logistical considerations in relapsed/refractory (r/r) iNHL.Recent findings: Several pivotal CAR-T trials have presented impressive response rates and durable remissions in r/r FL, while data in MZL is scarce. CAR-T is given as a single infusion, but requires a complex logistical infrastructure. Different BsAbs have shown favorable efficacy with a lower rate of acute toxicities. Off-the-shelve availability favors its usability, although prolonged administration of BsAbs might impose a substantial burden for patients. Long-term infection risk is a concern for both treatments. Clinical studies that directly compare CAR-T and BsAbs are still lacking.Summary: Both CAR-T and BsAbs have demonstrated promising efficacy as treatment modalities in iNHL. Decision making for T-cell engaging therapies should be tailored to patient specific factors and availability. Maturation of follow-up data will further guide evidence-based treatment choices in FL and MZL.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"393-400"},"PeriodicalIF":2.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCO.0000000000001160","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent subtypes of non-Hodgkin lymphoma (iNHL) characterized by a relapsing-remitting disease course. A promising novel therapeutic class emerges with T-cell engaging therapies, which include CD19 directed chimeric antigen receptor T-cell (CAR-T) therapy and CD3xCD20 directed bispecific antibodies (BsABs). This review provides a comprehensive evaluation of their efficacy and safety along with logistical considerations in relapsed/refractory (r/r) iNHL.

Recent findings: Several pivotal CAR-T trials have presented impressive response rates and durable remissions in r/r FL, while data in MZL is scarce. CAR-T is given as a single infusion, but requires a complex logistical infrastructure. Different BsAbs have shown favorable efficacy with a lower rate of acute toxicities. Off-the-shelve availability favors its usability, although prolonged administration of BsAbs might impose a substantial burden for patients. Long-term infection risk is a concern for both treatments. Clinical studies that directly compare CAR-T and BsAbs are still lacking.

Summary: Both CAR-T and BsAbs have demonstrated promising efficacy as treatment modalities in iNHL. Decision making for T-cell engaging therapies should be tailored to patient specific factors and availability. Maturation of follow-up data will further guide evidence-based treatment choices in FL and MZL.

查看原文本刊更多论文

t细胞参与治疗复发/难治性惰性非霍奇金淋巴瘤的前景

综述目的：滤泡性淋巴瘤（FL）和边缘区淋巴瘤（MZL）是非霍奇金淋巴瘤（iNHL）的惰性亚型，其特点是疾病过程复发缓解。一种有前景的新型治疗方法是t细胞结合疗法，包括CD19定向嵌合抗原受体t细胞（CAR-T）疗法和CD3xCD20定向双特异性抗体（BsABs）。这篇综述提供了它们在复发/难治性iNHL （r/r）中的有效性和安全性以及后勤考虑的综合评价。最近的发现：几个关键的CAR-T试验在r/r FL中显示了令人印象深刻的缓解率和持久的缓解，而MZL的数据很少。CAR-T是单次输注，但需要复杂的后勤基础设施。不同的bsab显示出良好的疗效和较低的急性毒性发生率。尽管长期服用bsab可能会给患者带来沉重的负担，但现货供应有利于其可用性。长期感染风险是这两种治疗的一个问题。直接比较CAR-T和bsab的临床研究仍然缺乏。摘要：CAR-T和bsab作为治疗iNHL的方法都显示出了良好的疗效。t细胞介入疗法的决策应根据患者的具体因素和可用性进行调整。成熟的随访数据将进一步指导FL和MZL的循证治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Oncology 医学-肿瘤学

CiteScore

6.10

自引率

2.90%

发文量

130

审稿时长

4-8 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Oncology offers expert evaluation on a wide range of topics from sixteen key disciplines including sarcomas, cancer biology, melanoma and endocrine tumors. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by annotated references detailing the merits of the most important papers.